Evaluation of the synergetic radio-chemotherapy effects of the radio labelled cisplatin for the treatment of glioma

The proposal of this work was to investigate the effect of the radioactive (NH 3 ) 2 PtCl 2 , cis -diamminedichloroplatinum (II) or CDDP* on malignant glioma cells and verify if the low-dose continuous internal radio-chemotherapy would be able to produce additive effects. The antitumoral activity of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of radioanalytical and nuclear chemistry 2012-04, Vol.292 (1), p.61-65
Main Authors: Soares, Marcela Araugio, Mattos, Juliana Lage, Pujatti, Priscila Brunelli, Leal, Alexandre Soares, dos Santos, Wagner Gouvêa, dos Santos, Raquel Gouvêa
Format: Article
Language:English
Subjects:
Cancer
Chemistry
Chemistry and Materials Science
Chemotherapy
Cisplatin
Diagnostic Radiology
Drug therapy
Gliomas
Hadrons
Heavy Ions
Inorganic Chemistry
Nuclear Chemistry
Nuclear Physics
Physical Chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The proposal of this work was to investigate the effect of the radioactive (NH 3 ) 2 PtCl 2 , cis -diamminedichloroplatinum (II) or CDDP* on malignant glioma cells and verify if the low-dose continuous internal radio-chemotherapy would be able to produce additive effects. The antitumoral activity of CDDP* and the non labeled cisplatin, CDDP, were evaluated in glioblastoma. Cisplatin was cytotoxic for glioblastoma cells in a dose dependent manner. Treatment with CDDP*, (IC 50  = 1.75 ± 0.07 μM), proved to be more potent than using just CDDP, (IC 50  = 4.96 ± 0.40 μM). These results suggest that cisplatin is a very potent radiosensitizer evoking a supra additive effect. Internal radio-chemotherapy treatment based on CDDP* may be useful alternative to reduce the drug concentration required for effective inhibition of glioblastoma growth.
ISSN:0236-5731
1588-2780
DOI:10.1007/s10967-011-1414-2